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SUMMARY
The cyclin-dependent kinases Cdk4 and Cdk6 form complexes with D-type cyclins to drive cell 
proliferation. A well-known target of cyclin D-Cdk4,6 is the retinoblastoma protein Rb, which 
inhibits cell-cycle progression until its inactivation by phosphorylation. However, the role of Rb 
phosphorylation by cyclin D-Cdk4,6 in cell-cycle progression is unclear because Rb can be 
phosphorylated by other cyclin-Cdks, and cyclin D-Cdk4,6 has other targets involved in cell 
division. Here, we show that cyclin D-Cdk4,6 docks one side of an alpha-helix in the Rb C 
terminus, which is not recognized by cyclins E, A, and B. This helix-based docking mechanism is 
shared by the p107 and p130 Rb-family members across metazoans. Mutation of the Rb C-
terminal helix prevents its phosphorylation, promotes G1 arrest, and enhances Rb’s tumor 
suppressive function. Our work conclusively demonstrates that the cyclin D-Rb interaction drives 
cell division and expands the diversity of known cyclin-based protein docking mechanisms.
In Brief
Precise timing of cell-cycle transitions relies on regulation of the activity and specificity of cyclin-
dependent kinases. Topacio et al. show that the G1 cyclin-Cdk complex cyclin D-Cdk4,6 targets its 
well-known substrate, the retinoblastoma protein Rb, through recognition of a C-terminal alpha-
helix and demonstrate that this specific cyclin-Cdk-substrate interaction drives cell proliferation.
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INTRODUCTION
The cyclin-dependent kinases Cdk4 and Cdk6 (Cdk4,6) are activated by the D-type cyclins 
D1, D2, and D3 (cyclin D) to drive cell-cycle progression from G1 to S phase (Morgan, 
1997; Sherr and Roberts, 2004). One important target of Cdk4,6 is the retinoblastoma tumor 
suppressor protein Rb, which binds and inhibits the activating E2F transcription factors. Rb 
phosphorylation promotes its dissociation from E2Fs and thereby drives the expression of 
E2F-target genes that initiate DNA replication (Bertoli et al., 2013; Dick and Rubin, 2013; 
Sherr and McCormick, 2002). The importance of Rb phosphorylation and the frequent 
observation of increased Cdk4,6 activity in cancer has contributed to the consensus model 
that these kinases, activated by their D-type cyclin partners, phosphorylate and inhibit Rb to 
drive cell-cycle progression (Burkhart and Sage, 2008; Lundberg and Weinberg, 1998).
In the current model, cyclin D-Cdk4,6 activity gradually increases until it triggers a positive 
feedback loop that commits cells to passing the restriction point just prior to the G1/S 
transition (Merrick et al., 2011; Pardee, 1974; Schwarz et al., 2018). As cells progress 
through G1, cyclin D-Cdk4,6 gradually phosphorylates Rb and triggers the onset of E2F-
dependent expression of cyclins E and A (Bertoli et al., 2013). Cyclins E and A then bind 
Cdk1 and Cdk2 to form complexes that continue to phosphorylate Rb (Merrick et al., 2011; 
Morgan, 2007; Narasimha et al., 2014). In addition, cyclin E- and A-dependent Cdk 
complexes phosphorylate and inhibit the E3 ubiquitin ligase APC/C activating subunit Cdh1, 
stabilizing APC/CCdh1 substrates, including cyclin A (Di Fiore et al., 2015; Jaspersen et al., 
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1999; Kramer et al., 2000; Zachariae et al., 1998). The sequential activation of these 
interconnected positive feedback loops progressively drives commitment to cell division in 
the face of exposure to anti-proliferative conditions (Cappell et al., 2016, 2018; Pardee, 
1974; Schwarz et al., 2018; Yung et al., 2007; Zetterberg and Larsson, 1985).
However, in opposition to the prevailing model of gradually increasing cyclin D-Cdk4,6 
activity triggering G1/S, cyclin D levels are nearly constant through G1 (Hitomi and Stacey, 
1999). Moreover, Rb is mono-phosphorylated during early- to mid-G1, suggesting that 
cyclin D-Cdk4,6 activity does not gradually increase through G1 (Narasimha et al., 2014). 
E2F-dependent transcription increases at the same time that Cdk2 activity increases in late 
G1, implying that cyclin D-dependent mono-phosphorylated Rb is still capable of 
interacting with E2F transcription factors to inhibit transcription. This raises the possibility 
that Rb inactivation in late G1 is due to hyper-phosphorylation by Cdk2 kinase complexes, 
and cyclin D-Cdk4,6 promotes the G1/S transition through a different mechanism 
(Narasimha et al., 2014).
If not Rb, what could be the main target of cyclin D-Cdk4,6 driving cell-cycle progression? 
Possible substrates, whose phosphorylation promotes cell-cycle progression, include a 
mediator of antiproliferative transforming growth factor β (TGF-β) signaling Smad3 
(Matsuura et al., 2004), an APC/C co-activator Cdh1 (The et al., 2015), and a cell-cycle 
transcription factor FOXM1 (Anders et al., 2011). Further supporting an oncogenic role for 
Cdk4,6, there is a growing body of literature showing that Cdks directly phosphorylate 
metabolic enzymes to regulate metabolism in yeast and human cells (Ewald, 2018; Ewald et 
al., 2016; Salazar-Roa and Malumbres, 2017; Zhao et al., 2016). More specifically, in 
mammalian cells, cyclin D3-Cdk6 kinase complexes phosphorylate and inactivate the key 
glycolytic enzymes PFKP and PKM2 to shunt glycolytic intermediates toward NADPH and 
GSH production, which mitigates ROS accumulation to promote cell survival (Wang et al., 
2017). These Rb-independent roles for cyclin D-Cdk4,6 in promoting cell proliferation raise 
the question as to what is the in vivo function of the cyclin D-Cdk4,6-Rb interaction.
To determine the function of Rb phosphorylation by cyclin D-Cdk4,6, we sought to generate 
variants of Rb that could no longer interact with cyclin D-Cdk4,6 while preserving all the 
other interactions with other cyclin-Cdk complexes. The specificity of substrate binding and 
phosphorylation by cyclin-Cdk complexes is generally determined by the ability of the 
cyclin to recognize docking sites on substrates (Morgan, 2007). Previously identified 
docking sites on substrates are short linear amino acid motifs. In budding yeast, the G1 
cyclin Cln2 recognizes an LP docking motif and the S phase cyclins Clb5 and Clb3 
recognize substrates with RxL docking motifs (Bhaduri and Pryciak, 2011; Cross and 
Jacobson, 2000; Kõivomägi et al., 2011; Loog and Morgan, 2005). In animal cells, cyclin A-
Cdk2 and cyclin E-Cdk2 complexes also utilize RxL-based docking through their α1 helix 
hydrophobic patches to bind and phosphorylate substrate proteins including Rb, p107, p27, 
and Cdc6 (Adams et al., 1999; Hirschi et al., 2010; Russo et al., 1996; Schulman et al., 
1998; Takeda et al., 2001; Wohlschlegel et al., 2001). While cyclin D appears to have a 
hydrophobic patch on its α1 helix similar to cyclins E and A, it has not been shown if this 
patch also recognizes RxL motifs. Cyclin D has an N-terminal LxCxE motif, which binds 
Rb’s LxCxE cleft (Dick and Rubin, 2013; Dowdy et al., 1993). However, mutation of this 
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LxCxE cleft has only a modest effect in vivo suggesting that either the cyclin D-Rb 
interaction is of limited importance or that there exist additional docking interactions. 
Supporting the existence of an additional cyclin D-Rb docking interaction, truncation of the 
Rb C terminus disrupts phosphorylation by cyclin D1-Cdk4 in vitro, and this truncated Rb 
variant slows division and inhibits E2F-dependent gene expression in cultured cells (Gorges 
et al., 2008; Pan et al., 2001; Wallace and Ball, 2004).
In this study, we analyzed the docking interactions between Rb and cyclin D-Cdk4,6 
complexes. We found that cyclin D-Cdk4,6 targets the Rb family of proteins for 
phosphorylation primarily by docking a C-terminal alpha-helix. Importantly, this Rb C-
terminal helix is not recognized by the other major cell-cycle cyclin-Cdk complexes cyclin 
E-Cdk2, cyclin A-Cdk2, and cyclin B-Cdk1. Thus, mutation of this helix disrupts cyclin D’s 
ability to phosphorylate Rb and preserves Rb regulation by other cyclin-Cdk complexes. 
Disruption of helix-based docking reduced Rb phosphorylation, induced G1 cell-cycle arrest 
in cell lines, and slowed tumor growth in vivo. Taken together, our results show that cyclin 
D-Cdk4,6 phosphorylates and inhibits Rb via a C-terminal helix and that this interaction is a 
major driver of cell proliferation.
RESULTS
RxL- and LxCxE-Based Docking Mutations Broadly Affect Cyclin-Cdk Complexes
To determine the function of Rb phosphorylation by cyclin D-Cdk4,6, we sought to generate 
an Rb variant that does not interact with cyclin D-Cdk4,6, but does interact with other 
cyclin-Cdk complexes (Figures 1A and 1B). To identify specific cyclin D-Rb interactions, 
we performed in vitro kinase assays on Rb protein variants with a panel of purified cyclin-
Cdk complexes (Schwarz et al., 2018) (Figure S1). In contrast to other studies of Rb 
phosphorylation that used Rb fragments, we were able to purify full-length Rb protein from 
bacteria for our study. In these kinase assay experiments, mutation of Rb residues required 
for docking interactions manifest as reduced kinase activity toward Rb. Compared with other 
cyclin-Cdk complexes, cyclin D-Cdk4,6 exhibited no detectable kinase activity toward the 
model Cdk substrate histone H1 (Matsushime et al., 1994) but was capable of 
phosphorylating Rb (Figures 1C–1E).
To test the effect of mutating known cyclin D-Rb docking interactions, we first removed the 
LxCxE binding cleft in the Rb pocket domain that interacts with proteins containing the 
LxCxE motif, such as viral oncoproteins and cyclin D (Dick et al., 2000; Dowdy et al., 
1993; Markey et al., 2007). This resulted in only a 1.7-fold ± 0.3-fold reduction in 
phosphorylation by cyclin D kinase complexes (Figures 1C and S1L), consistent with 
reports that the LxCxE-docking interaction alone is weak and its removal has modest effects 
in cells (Dick et al., 2000; Guiley et al., 2015). Moreover, we observed that previously 
reported LxCxE cleft mutations similarly affected cyclin E-, A-, and B-dependent 
phosphorylation of Rb in vitro and therefore may not be specific for cyclin D (Figures 1C 
and S1L).
Next, we tested the effect of mutating the RxL motifs on Rb that are reported to interact with 
the hydrophobic patch region of the S phase cyclins E and A (Adams et al., 1999; Hirschi et 
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al., 2010; Schulman et al., 1998). We generated an Rb variant lacking all 5 RxL sequences in 
its unstructured regions (Figure 1A and 1B). Compared to wild type Rb, this RxL variant of 
Rb was phosphorylated 2.0-fold ± 0.1-fold less by cyclin E-Cdk2 and 2.9- fold ± 0.2-fold 
less by cyclin A-Cdk2 (Figures 1C and S1L). This implies that, while cyclins E and A use 
RxL docking as previously reported, this is not the only mechanism they use to identify their 
substrates. Cyclin B-Cdk1 phosphorylation of Rb was unchanged by mutating the RxL 
motifs, suggesting that cyclin B does not use its hydrophobic patch to phosphorylate Rb. 
While it has not been studied extensively, cyclin D has an α1 helix hydrophobic patch as 
cyclins E, A, and B, but it is composed of different amino acid residues (Morgan, 2007). We 
observed that the Rb variant lacking RxL motifs was phosphorylated 4.1- fold ± 0.4-fold less 
by cyclin D-Cdk4,6, suggesting that cyclin D recognizes RxL motifs as other cyclins 
(Figures 1C and S1L). While the RxL docking is clearly important for cyclin D, it is shared 
with other cyclins so that its mutation would not specifically disrupt the cyclin D-Rb 
interaction.
Cyclin D-Cdk4,6 Complexes Target Rb for Phosphorylation by Docking a C-Terminal Helix
To generate an Rb protein variant that does not interact with cyclin D-Cdk4,6, but does 
interact with other cyclin-Cdk complexes, we next examined the effect of truncating the final 
37 amino acids of Rb. Truncation of the Rb C terminus, which included these 37 amino 
acids, was previously shown to reduce Rb phosphorylation in vitro and promote Rb’s ability 
to arrest cells in G1 (Gorges et al., 2008; Pan et al., 2001; Wallace and Ball, 2004) (Figure 
S2). C-terminal truncation of Rb reduced phosphorylation by cyclin D1-Cdk4,6 20-fold 
± 10-fold (Figures 1C and S1L) and increased the Michaelis-Menten constant KM beyond 
our measurement limit of ~5 μM (Figure S2G), indicating the presence of a docking 
interaction in the final 37 amino acids of the Rb C terminus. Importantly, this C-terminal 
truncation is specific for cyclin D-Cdk4,6 complexes and does not affect the phosphorylation 
of Rb by cyclin E-Cdk2, cyclin A-Cdk2, and cyclin B-Cdk1 complexes (Figures 1C, 1F, and 
S2H).
We next sought to determine how the Rb C terminus promotes phosphorylation by cyclin D-
Cdk4,6. Cyclin substrate docking has previously been shown to arise from short linear 
motifs of a few amino acids in intrinsically disordered regions on the target proteins, a 
common mechanism for evolution of protein-protein interactions (Bloom and Cross, 2007; 
Davey et al., 2015). However, such a short linear motif model is unlikely to explain the 
interaction of cyclin D with the Rb C terminus because in vitro Rb phosphorylation by 
cyclin D-Cdk4 is affected by mutations over a large range of amino acids (Wallace and Ball, 
2004). While the Rb C terminus is intrinsically disordered, it is known to adopt structure 
when bound to other proteins (Rubin et al., 2005). We therefore examined the Rb C terminus 
for potential secondary structure and found a stretch of 21 amino acids with alpha-helix 
propensity (Rb 895–915; Figures 1G and S3). Deletion of this potential helix (ΔHelix) or 
disruption of this helix by proline substitution (Q899P or A902P) drastically reduced Rb 
phosphorylation by cyclin D-Cdk4,6, which was comparable to the phosphorylation of an 
Rb variant (ΔCdk) lacking all 14 accessible Cdk phosphorylation sites (Figures 1G, 1H, 
S2A, and S2B).
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The Rb C-terminal helix is predicted to have one face composed primarily of hydrophobic 
residues (Figure 1G). We tested whether these residues could form an interface between the 
Rb C-terminal helix and cyclin D-Cdk4,6 by measuring phosphorylation of alanine 
substitution mutants by cyclin D-Cdk4. Rb phosphorylation was disrupted when individual 
predicted interface residues were mutated but was unaffected when individual adjacent 
residues were mutated (Figure S2C). For example, the impact of arginine-to-alanine 
substitutions depended on which face of the helix it occurred on (Figures 1G and 1H; 
compare R908A versus R910A). Combined alanine substitution of three of the core interface 
residues (F897, L901, and R908), denoted as RbHelix mut, disrupted phosphorylation of Rb 
by cyclin D-Cdk4,6 similar to that of RbΔHelix (Figures 1G, 1H, and S2D). To test whether 
the orientation of the helix was important for phosphorylation, we reversed the primary 
sequence of the helix within the C terminus of full-length Rb. This variant (rev. Helix) was 
poorly phosphorylated by cyclin D-Cdk4, suggesting that the orientation of the interface is 
important for docking in addition to the polarity and acid-base properties of the interface 
residues (Figure S2D).
Because alanine has high helical propensity (Pace and Scholtz, 1998), these substitutions 
likely disrupt the recognition of Rb by cyclin D-Cdk4,6 without affecting the C-terminal 
helix structure. We found that alanine substitution of the core interface residues did not 
change alpha-helix propensity (Figure S3B) and confirmed that the core interface mutations 
disrupted cyclin D-Cdk4,6 binding to Rb with GST-pull-down assays (Figures 1I and 1J).
Finally, we examined the effect of combining mutations on Rb and found that LxCxE, RxL, 
and helix mutations were additive (Figures 1K, 1L, and S2G). This suggests that these 
docking sites interact with different parts of cyclin D, but it is unclear why disruption of only 
two of three available cyclin D docking mechanisms can render Rb unphosphorylatable in 
vitro. Taken together, our analysis reveals a mechanism of helix-based docking for cyclin D-
Cdk4,6 within a diverse set of poorly understood docking interactions distinct for each 
cyclin (Figure 1M).
Cyclin D1-Cdk4,6 Phosphorylates Synthetic Substrates Fused to the Rb C-Terminal Helix
To further test the helix-based docking model, we sought to confer increased cyclin D 
activity to poor Cdk4,6 substrates such as an Rb peptide containing a single Cdk consensus 
phosphorylation site (Grafström et al., 1999; Kitagawa et al., 1996). To do this, we generated 
a fusion protein containing a GST tag, Rb amino acids 775–790 that contain a single Cdk 
site, a Gly-Ser linker, and the Rb C-terminal helix (Figures 2A and S4; Table S1). Fusing the 
helix to this previously poor substrate led to a 13.9 fold ± 0.1-fold increase in 
phosphorylation by cyclin D1-Cdk6 but did not affect phosphorylation by cyclin E1-Cdk2 
(Figures 2B and 2C). We also observed a similar increase in activity toward fusion proteins 
containing single Cdk sites on peptides derived from Histone H1 (Matsushime et al., 1994) 
or Rb amino acids 790–805 (Figures S4G and S4H). Cyclin D1-Cdk6 did not phosphorylate 
synthetic substrates containing the Rb C-terminal helix with the predicted core interface 
residues substituted with alanines (Figures 2B, S4C, S4F, and S4G). We again tested the 
impact of the orientation of these interface residues on docking by generating a synthetic 
substrate containing a reversed Rb C-terminal helix. Our observation that this synthetic 
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substrate was poorly phosphorylated by cyclin D1-Cdk6 is consistent with our data 
suggesting that the orientation of the C-terminal helix is critical for docking of full-length 
Rb (Figures 2A, 2B, S2C, S4C, and S4F). Moreover, fusion of the Rb C-terminal helix did 
not affect the phosphorylation of these synthetic substrates by cyclin E1-Cdk2, further 
supporting that the Rb C-terminal helix is specific for cyclin D-Cdk4,6 complexes (Figures 
2C–2E, S4D, S4F, and S4H). Taken together, these data show that the Rb C-terminal helix is 
sufficient to direct cyclin D-Cdk4,6 complexes for phosphorylation, regardless of intrinsic 
preferences for particular Cdk sites since it enhances phosphorylation for both the relatively 
weak and strong Cdk phosphorylation sites that we tested (Figure S4).
D-Type Cyclins Recognize the Rb C-Terminal Helix
To determine the subunit of the cyclin D-Cdk4,6 complex that interacts with the Rb C-
terminal helix, we generated the remaining D-type cyclin-Cdk complexes formed by cyclins 
D2 and D3 with Cdk4 and Cdk6. All six cyclin D-Cdk4,6 complexes target Rb for 
phosphorylation through helix-based docking (Figure 3A). Because all three D-type cyclins 
have the α1 helix hydrophobic patch, we sought to determine what the cyclin D hydrophobic 
patch recognized. To do this, we purified Cdk6 in complex with a cyclin D1 variant in which 
the residues that form the hydrophobic patch were substituted with alanines (cyclin 
D1HP mut.). Compared to wild type cyclin D1-Cdk6, cyclin D1HP mut-Cdk6 exhibited weaker 
kinase activity toward Rb consistent with a function for the hydrophobic patch (Figure 3B). 
However, cyclin D1Hp mut.-Cdk6 did not phosphorylate an Rb variant where the C-terminal 
helix interface residues were substituted with alanines. This implies that the hydrophobic 
patch is not responsible for recognizing the Rb C-terminal helix (Figure 3B).
To test if cyclin D’s hydrophobic patch docks RxL sequences similar to cyclin A and E 
(Adams et al., 1999; Hirschi et al., 2010; Schulman et al., 1998; Takeda et al., 2001), we 
compared the ability of cyclin D1-Cdk6 and cyclin D1HP mut.-Cdk6 to phosphorylate 
synthetic substrates containing an RxL motif. Mutation of the cyclin D hydrophobic patch 
removed the ability of cyclin D1-Cdk6 to phosphorylate a fusion protein containing a GST 
tag, the Rb amino acids 775–790 containing a single Cdk site, and a peptide containing an 
RxL sequence derived from the known Cdk substrate Cdc6 (Takeda et al., 2001) (Figures 
3C, 3D, and S4E). However, the cyclin D hydrophobic patch mutation did not affect the 
ability of cyclin D1-Cdk6 to phosphorylate a fusion protein where the RxL docking 
sequence was replaced by the Rb C-terminal helix (Figures 3C and 3D). As expected, 
mutation of the LxCxE sequence in cyclin D did not affect phosphorylation of any of these 
substrates (Figures 3C and 3E). Taken together, these data suggest that the hydrophobic 
patch on cyclin D recognizes linear RxL sequences, including those on Rb.
That cyclin D’s hydrophobic recognized RxL sequences but not the Rb C-terminal helix 
raised the question if cyclin D or Cdk4,6 was responsible for helix docking. To test if cyclin 
D was responsible for helix-based docking, we purified cyclin D1-Cdk2 complexes and 
observed that cyclin D1-Cdk2 complexes phosphorylate synthetic substrates containing the 
C-terminal helix (Figure 3F). Because cyclin E1-Cdk2 complexes do not use helix docking 
but cyclin D1-Cdk2 complexes can use helix-based docking, our experiments suggest that 
the helix-docking site likely lies on cyclin D rather than Cdk4,6. Thus, the hydrophobic 
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patch of cyclin D likely recognizes RxL sequences, while a different region on cyclin D is 
likely responsible for recognizing the Rb C-terminal helix (Figure 3G).
A C-Terminal Docking Helix Is Present across the Metazoan Rb Protein Family
We next examined if other cyclin D-Cdk4,6 substrates used helix-based docking. As few 
Cdk4,6 substrates are known (Anders et al., 2011; Malumbres and Barbacid, 2005), we 
initially examined the Rb family members, p107 and p130, which are similar in sequence 
and function (Dick and Rubin, 2013). We hypothesized that all human and mouse Rb family 
proteins, based on their sequence, have C-terminal docking helices and found that they were 
targeted by cyclin D-Cdk4,6 in vitro (Figures 4A–4D and S5). Alanine substitutions at 
residues we predict to be the docking interface for p107 and p130 also disrupted 
phosphorylation by cyclin D1-Cdk4 (Figures 4A–4D). We observed a similar requirement 
for helix-based docking with mouse Rb (Figures S5K and S5L). The presence of helix-based 
docking across the Rb family led us to search for the conserved sequence motif, which we 
identified by aligning 682 C-terminal sequences of metazoan Rb family members (Medina et 
al., 2016) and generating a consensus sequence motif (Figure 4E). We did not find such C-
terminal helices in Rb sequences outside metazoans, suggesting that helix-based docking is a 
metazoan innovation (Figure 4F). Taken together, our results suggest that cyclin D-Cdk4,6 
targets the Rb family through a similar mechanism across metazoans. A motif search 
through the human proteome looking for such docking helices on proteins containing Cdk 
consensus phosphorylation sites suggests as many as 70 proteins may use this mechanism 
(Table S2).
The Cyclin D-Rb Interaction Promotes the G1/S Transition, Rb Dissociation from 
Chromatin, and E2F1 Activation
The identification of the Rb C-terminal helix allowed us to test the function of Rb 
phosphorylation by cyclin D-Cdk4,6 in cell-cycle control. This is because mutation of Rb’s 
C-terminal helix disrupts phosphorylation by cyclin D-Cdk4,6, but not other cell-cycle-
dependent cyclin-Cdk complexes so that the introduction of Rb C-terminal helix mutations 
specifically tests the function of the cyclin D-Rb interaction.
To test the function of the cyclin D-Rb interaction, we examined immortalized human 
mammary epithelial cells (HMECs) expressing doxycycline-inducible Rb variant proteins 
fused to Clover fluorescent protein and 3FLAG affinity tags (Figures 5A, 5B, S6A and S6B). 
We chose to examine HMECs because they are a non-transformed cell line previously used 
to study cell growth and proliferation (Sack et al., 2018). Expression of exogenous wild type 
Rb in HMECs had a minor effect on cell-cycle progression and cell size, whereas expression 
of RbHelix mut., which lacks helix-based docking, increased the fraction of cells in G1 from 
50% to 75%, and increased cell size by 55% (Figures 5C and 5D). Expression of RbHelix mut. 
had a similar effect to exposing cells to 500 nM palbociclib, a Cdk4,6 inhibitor (Figure 5C). 
Expression of the double mutant RbLxCxE cleft+Helix mut. protein, which lacks LxCxE- and 
helix-based docking mechanisms, resulted in a dramatic G1 cell-cycle arrest and a cell size 
increase similar to the effect of expressing an RbΔCdk protein lacking all 14 Cdk 
phosphorylation sites (Figures 5C and 5D). The cell size and cell-cycle phase phenotypes 
correlated with the amount of chromatin-bound Clover-3FLAG-Rb in G1 phase cells for 
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each Rb variant (Figure 5E). More specifically, following a low salt wash (Håland et al., 
2015; Lundberg and Weinberg, 1998), there was 11.5-fold more RbΔCdk than wild type Rb 
that remained bound to chromatin in G1 in a representative experiment. These effects were 
not due to differences in Rb protein expression as measured using a quantitative immunoblot 
(Figures S6A and S6B). We also examined Rb variant expression in an Rb-deficient U-2 OS 
cell line and observed that both U-2 OS and U-2 OS RB1−/− cell lines responded to 
exogenous Rb expression similarly to HMECs. In these cell lines, RbHelix mut. caused a 
greater increase in the G1 fraction of cells than wild type Rb (Figure S6C).
Next, we examined the phosphorylation of exogenously expressed wild type Rb and 
RbHelix mut. in T98G cells that were arrested and synchronously released into the cell cycle 
following serum starvation (Figure 5F). Cells expressing RbHelix mut. displayed less 
phosphorylated Rb and had weaker E2F1 expression, suggesting that cyclin D-Cdk4,6-
dependent phosphorylation during G1 is important for E2F1-dependent transcription and 
cell-cycle entry (Figure 5G–5l). We chose to examine E2F1 expression because it is a target 
of activating E2F transcription factors (Johnson et al., 1994). Consistent with helix-based 
docking being important for activating E2F-dependent gene expression, we observed lower 
E2F1 protein levels in cells expressing the RbHelix mut. variant compared to wild type Rb 
(Figure 5I). Taken together, these experiments are consistent with our biochemical results 
and show the additive effect of disrupting LxCxE- and helix-based docking mechanisms. 
Moreover, our analysis strongly supports the role of the cyclin D-Rb interaction as a critical 
driver of cell-cycle entry at the G1/S transition.
Disruption of the Cyclin D-Rb Interaction Slows Tumor Growth
We next sought to test our model that cyclin D docks the Rb C-terminal helix to promote 
cell-cycle progression in an animal model. To determine if the Rb variant lacking helix-
based docking, RbHellx mut., is a more potent tumor suppressor than wild type Rb, we 
integrated a vector containing doxycycline-inducible Rb alleles into a Kras+/G12D; Trp53−/− 
mouse pancreatic ductal adenocarcinoma cell line (Mazur et al., 2015) (Figures 6A, S6D, 
and S6E). We then allografted these cell lines into NSG mice by subcutaneous implantation. 
Tumors were allowed to engraft and grow for 5 days before we induced expression of the 
exogenous Rb alleles (Figure 6A). The tumor suppressor function of Rb was enhanced in the 
RbHelix mut. variant lacking helix-based docking and was more enhanced by the removal of 
the Cdk sites as in RbΔCdk (Figure 6B; see Figure S7 for fold changes and p values for all 
genotype comparisons). At the end of a biological replicate experiment, tumors were 
extracted and weighed, further demonstrating the difference between the tumor suppressor 
potency of wild type Rb and RbHelix mut. (Figure 6C). Interestingly, we did not find an 
additive effect when an LxCxE cleft mutation, RbLxCxE cleft mut., was combined with either 
wild type Rb or RbHelix mut. (Figure S7), consistent with the previously reported mild 
phenotype of this mutation (Dick et al., 2000). Our results here support the model in which 
the cyclin D-Rb helix docking interaction drives Rb inactivation and cell-cycle progression 
in vivo.
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DISCUSSION
Taken together, our work demonstrates the importance of helix-based cyclin D docking on 
Rb to promote phosphorylation, drive cell-cycle progression, and inhibit Rb’s tumor 
suppressive function. This study was motivated by the apparent conflict between the long-
standing model of the G1/S transition and recent reports that cyclin D-Cdk4,6 may drive cell 
proliferation and survival through Rb-independent mechanisms. We identified a C-terminal 
helix in Rb that specifically docks cyclin D (Figure 7A). Mutation of the Rb C-terminal 
helix disrupts its interaction with cyclin D but preserves the ability of other cyclin-Cdk 
complexes to phosphorylate Rb. Expressing Rb protein variants lacking the C-terminal helix 
arrested cells in G1 and slowed tumor growth even though cyclin D-Cdk4,6 could still 
interact with all of its other targets. A model where cyclin D inhibits Rb indirectly through 
downstream cyclins is therefore unlikely because these Rb variants lacking the docking helix 
are readily targeted by downstream cyclins E and A. Thus, Rb phosphorylation by cyclin D-
Cdk4,6 is a crucial first step in driving the G1/S transition.
While Rb is clearly an important target for cyclin D to promote cell proliferation, it may not 
be the only such target. Although we believe the major cell-cycle function of cyclin D-
Cdk4,6 is to inactivate and phosphorylate Rb through helix-based docking, the complex also 
independently influences cell survival by phosphorylating and inactivating metabolic 
enzymes. Thus, cell proliferation in vivo may be enhanced by increasing cell survival and by 
driving cell division through distinct cyclin D-Cdk4,6 targets (Figure 7B). By examining Rb-
docking helices across metazoans, we identified a consensus helix sequence motif, which we 
then used to generate a list of potential substrates in the human proteome (Table S2). This 
list may provide more insight into non-canonical substrates and functions of cyclin D-
Cdk4,6 that could promote proliferation.
In general, progression through the eukaryotic cell cycle is characterized by a monotonic 
increase in cyclin-dependent kinase activity (Stern and Nurse, 1996). However, not all cell-
cycle-dependent substrates are phosphorylated at the same time (Swaffer et al., 2016, 2018). 
Early substrates are typically targets of early cyclin-Cdk complexes via specific docking 
mechanisms (Loog and Morgan, 2005). To prevent later substrates from being 
phosphorylated by the early activated cyclin-Cdk complexes, these early complexes are 
typically characterized by lower intrinsic kinase activity. For example, in budding yeast, 
peptides containing a single Cdk site derived from histone H1 were phosphorylated at 
progressively higher rates by G1-phase, S-phase, and mitotic cyclins (Kõivomägi et al., 
2011). Here, we report a similar progressive increase in intrinsic kinase activity toward 
histone H1 by animal cyclin-Cdk complexes. By far, the lowest activity toward H1 was 
found in cyclin D-Cdk4,6 complexes. Thus, the progression of the cell cycle from high-
specificity cyclin-Cdk complexes through to high-activity complexes is likely a conserved 
feature of eukaryotic cell-cycle control.
The low activity of cyclin D-Cdk4,6 complexes may be compensated for by the specificity 
of their docking mechanisms. In contrast to previously identified cyclin-Cdk docking motifs, 
which are short linear motifs in intrinsically disordered regions of proteins, Rb helix-based 
docking is unique in its structural requirement. While short linear motifs are easy to evolve 
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(Davey et al., 2015), the addition of a structural requirement, such as a helix, likely makes it 
much more difficult. This is because both the helix and the appropriate interface residues 
must align. The difficulty of evolving helix-based docking could therefore underlie the 
observation that cyclin D-Cdk4,6 appears to have relatively few substrates compared to other 
cyclin-Cdk complexes (Anders et al., 2011; Malumbres and Barbacid, 2005). We speculate 
that this low-activity, high-docking-specificity kinase has few substrates so it may 
adequately phosphorylate key targets, such as Rb.
Cyclin D-Cdk4,6 complexes clearly play a role in cancer, and a series of cancer drugs 
targeting the ATP pockets of Cdk4,6 are successfully emerging from clinical trials (Sherr et 
al., 2016). However, while Cdk4,6 inhibitors such as palbociclib have been observed to limit 
disease progression, the differences in overall survival compared to standard of care are not 
statistically significant (Finn et al., 2016; Turner et al., 2018). That Cdk4,6 inhibitors have 
significant off-target activities (Hafner et al., 2017) raises the possibility that these cancer 
therapies can be improved by a new class of drugs targeting cyclin substrate recognition and 
helix-based docking.
STAR★METHODS
Detailed methods are provided in the online version of this paper and include the following:
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Jan M. Skotheim (skotheim@stanford.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture and Transfection—Immortalized human mammary epithelial cells HMEC-
hTERT1 cells were cultured in MEGM Mammary Epithelial Cell Growth Medium (Lonza 
CC-3150) (Sack et al., 2018). T98G, CKP-2167, and U-2 OS cells were cultured in DMEM 
supplemented with 10% FBS, 4.5g/L Glucose, 2 mM L-glutamine, and Sodium Pyruvate 
(Mazur et al., 2015). Cell lines stably expressing doxycycline-inducible Rb variants were 
generated by transfecting cells plated into individual wells of a 6 well dish with 2.2 mg of 
doxycycline-inducible PiggyBac integration plasmid and 1.1 mg of PiggyBac Transposase 
plasmid (Ding et al., 2005) using the FuGene HD reagent (Promega E2311). Zeocin 
(400ug/mL) selection began two days after transfection. Zeocin resistant cells were 
maintained as polyclonal cell lines. Prior to flow cytometry and immunoblot analysis, cells 
were grown in the presence of doxycycline (500 ng/mL) for two days.
Doxycycline-inducible PiggyBac integration vector construction—We cloned an 
Rb expression cassette, driven by the TRE3G doxycycline-inducible promoter (Clontech 
631168), into a PiggyBac integration plasmid containing 5′ and 3′ PiggyBac homology 
arms (Ding et al., 2005; Shariati et al., 2018). The expression cassette contains the human 
RB1 or mouse Rb1 genes fused to fluorescent Clover and 3FLAG affinity tag sequences, a 
zeocin resistance gene, and a Tet-On 3G transactivator gene driven by the Ef1α promoter.
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Subcutaneous tumor implantation—CKP-2167 expressing variants of doxycycline-
inducible mouse Rb were allografted by subcutaneous implantation in NSG mice. For each 
implantation, approximately 1 million cells were suspended in 100 μL of 1X PBS and mixed 
with 100 μL of Matrigel Basement Membrane Matrix (Corning 356237). This mixture was 
injected into the left and right flanks of each mouse. After five days of engraftment and 
growth, mice were given water supplemented with doxycycline (2 mg/mL) for two weeks. 
Tumor lengths and widths were measured with calipers and volumes were estimated with the 
formula V= (4/3) × π × r3, where r is half of the average tumor diameter or (length + width) 
÷ 4. At the end of the experiment, mice were sacrificed, and tumors were harvested. Animal 
studies were done in compliance with the Stanford Administrative Panel on Laboratory 
Animal Care Protocol 13565.
METHOD DETAILS
Protein expression and purification—Full-length, N-terminally glutathione S-
transferase-tagged (GST-tagged), Rb family proteins were expressed in the E. coli strain 
BL21, purified by glutathione-agarose affinity chromatography (Sigma-Aldrich G4510), and 
eluted with 50mM Tris pH 8.0; 100mM KOAc; 25mM MgOAc; 10% glycerol; 15mM 
Glutathione (Sigma-Aldrich G4251).
GST-Cdk phosphorylation site fusion proteins (Figure S4; Table S1) containing a GST tag, a 
TEV-protease cleavage site, and a single Cdk phosphorylation site peptide were expressed 
and purified as described above. The three different Cdk phosphorylation sites that we used 
were (1) a Cdk site patterned after a region of similar sequence found in histone H1 protein 
(Hagopian et al., 2001; Kõivomägi et al., 2011) (H1 site: PKTPKKAKKL), (2) an S780 Cdk 
site from Rb (Kitagawa et al., 1996) (Rb 775–787: RPPTLSPIPHIPR), and (3) an S795 Cdk 
site from Rb (Grafström et al., 1999) (Rb 790–805: YKFPSSPLRIPGGNIY). To test 
docking specificity of the cyclin-Cdk complexes, we also fused these GST-Cdk site fusion 
proteins to the Rb C-terminal Helix (Rb 895–915: SKFQQKLAEMTSTRTRMQKQK) or 
the Cdc6 RxL docking motif (Takeda et al., 2001) (Cdc6 89–103: HTLKGRRLVFDNQLT) 
using a G4S glycine-serine linker (GGGGS).
Human cyclin-Cdk fusion complexes were purified from budding yeast cells (Schwarz et al., 
2018) using a 3X FLAG affinity purification method, modified from a previous protocol 
used for HA-tag purification (McCusker et al., 2007). Briefly, N-terminally tagged cyclin-
Cdk fusions were cloned into 2-micron vectors using a glycine-serine linker (Rao et al., 
1999) and overexpressed from the GAL1 budding yeast promoter. The overexpressed 
3FLAG-tagged cyclin-Cdk complexes were then purified by immunoaffinity 
chromatography using ANTI-FLAG M2 affinity agarose beads (Sigma-Aldrich A2220) and 
eluted with 0.2 mg/mL 3X FLAG peptide (Sigma-Aldrich F4799). We note that similar 
cyclin-Cdk fusions have previously been able to restore wild-type function in vivo (Chytil et 
al., 2004).
In vitro kinase assays—For all experiments, equal amounts of substrate and purified 
kinase complexes were used. Substrate concentrations were kept in the range of 1–5 mM for 
different experiments, but did not vary within any experiment. Reaction aliquots were taken 
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at two time points (8 and 16 minutes) and the reaction was stopped with SDS-PAGE sample 
buffer. The basal composition of the assay mixture contained 50 mM HEPES pH 7.4, 20 
mM Tris pH 8.0, 150 mM NaCl, 5 mM MgCl2, 10 mM MgOAc, 40 mM KOAc, 6 mM 
glutathione, 0.2 mg/ml 3X FLAG peptide, 6% glycerol, 3 mM EGTA, 0.2 mg/ml BSA and 
500 μM ATP (with 2 μCi of [γ−32P] ATP added per reaction; PerkinElmer 
BLU502Z250UC). Histone H1 protein used as a general substrate for Cdk was purchased 
from EMD Millipore (14–155). Phosphorylated proteins were separated on 10% SDS-PAGE 
gels. Phosphorylation of substrate proteins was visualized using autoradiography (Typhoon 
9210; GE Healthcare Life Sciences). Autoradiographs were quantified with the ImageQuant 
TL Software. We note that phosphorylation of H1 and Rb by our cyclin-Cdk fusions occurs 
in the linear range for the 8- and 16-minute time-points (Figures S1D–S1K). Within every 
experiment and quantification, the reactions have been conducted at the same time, run on 
the same gel, and images were taken of the same exposures. The few cases in which the gels 
were cropped (Figure S1B) were done to rearrange the order of lanes to increase figure 
clarity.
Glutathione S-transferase (GST) pull down assay—GST-tagged Rb proteins were 
dialyzed to remove glutathione using a buffer containing 50mM Tris pH 8.0, 100mM KOAc, 
25mM MgOAc, and 10% glycerol. Next, GST-Rb proteins were bound to glutathione-
agarose beads (Sigma-Aldrich G4510) for 1 hour at 4°C in a binding buffer containing 50 
mM Tris pH 8.0,150 mM NaCl, 1% Triton X-100, and 1 mM DTT. This bead-GST-Rb 
mixture was washed with this binding buffer and incubated with an equimolar amount of 
3FLAG-tagged cyclin-Cdk complexes for 2–3 hours at 4°C. Beads were then washed with 
binding buffer and eluted with 2X SDS-PAGE sample buffer. Input and pulldown samples 
were then analyzed by immunoblotting.
Circular dichroism—Circular dichroism (CD) spectra were recorded using a Jasco J-1500 
CD spectrometer. Samples contained 30 μM recombinant Rb 890–920 in a buffer containing 
25 mM sodium phosphate and 100 mM NaCl (pH 6.1). The data were fit by calculating a 
weighted average of reference spectra measured for poly-L-lysine, which adopts known 
different secondary structures depending on pH and temperature (Greenfield and Fasman, 
1969).
Helix prediction, bioinformatics analysis, and helix motif search—Secondary 
structure predictions were carried out on the PSIPRED protein structure prediction server 
using the PSIPRED v3.3 Secondary Structure prediction method (Buchan et al., 2013) 
(http://bioinf.cs.ucl.ac.uk/psipred/). Helical wheel projections of predicted C-terminal 
helices were generated using the “Helical Wheel Projections” tool (http://rzlab.ucr.edu/
scripts/wheel/wheel.cgi).
The full-length sequences of Rb family members (Medina et al., 2016) were aligned by 
MAFFT-L-INS-I (Katoh et al., 2017). A profile Hidden-Markov model (HMM) was 
generated using the HMMER3 web service (Finn et al., 2015). JackHMMER used to 
iteratively search for Rb homologs based on the profile HMM, using a stringent E-value 
cutoff of 1e-10 against UniProt Reference Proteomes. Of the total 1072 eukaryotic Rb 
homologs retrieved, 682 were metazoan. All sequences were re-aligned using MAFFT-L-
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INS-i (maxitr = 1000). The aligned metazoan sequences were then trimmed to focus on 
sequence positions occupied by human Rb. Membership in RB1, RBL1, or RBL2 sub-
families were determined by manual examination of the phylogenetic tree generated using 
Fast Tree (Price et al., 2009). Non-metazoan Rb sequence from taxa closely related to 
metazoan were examined manually.
Aligned sequences from the helix region of metazoan RB family members were used to 
generate a position specific weight matrix (PSSM). The PSSM was used to score protein 
sequences in the UniProtKB/Swiss-Prot reviewed human proteome (UP000005640). 
PSIPRED was used perform helicity prediction on sequences with PSSM scores above 20, 
which corresponds to 5 standard deviation above the mean random score distribution). The 
sequences were further filtered by the presence of CDK substrate sites ([S/T]P) within the 
full-length protein. All analysis was done using BioPython (Cock et al., 2009). Results from 
helix motif search are listed in Table S2.
Flow cytometry analysis—Flow cytometry analysis was performed on BD LSRII.UV 
cytometer. Live cells were prepared for flow cytometry by washing with 1X PBS, 
trypsinizing, and resuspending in 1X PBS. For live cells, we measured forward scatter area 
as a readout for cell size. For measurement of newly synthesized DNA by nucleoside analog 
incorporation, cells were incubated with 10 μM EdUfor30 minutes at 37°C, fixed in 3% 
formaldehyde for 10 minutes at 37°C, and permeabilized with 90% ethanol for 30 minutes 
on ice. EdU was detected using the Click-iT Plus EdU Alexa Fluor 594 Flow Cytometry 
Assay Kit (C10646) and cells were stained with 3 μM DAPI for 10 minutes at room 
temperature. For these fixed cells, we measured EdU, DAPI fluorescence as a readout for 
DNA content, Clover green protein fluorescence as a readout for the amount of tagged 
exogenous Rb, and forward scatter area as a readout for cell size. To measure the amount of 
DNA-associated Rb, we used a soluble protein extraction method (Håland et al., 2015). 
Briefly, the cells were harvested by trypsinization and pelleted by centrifugation. The cell 
pellet was then resuspended in ice-cold low salt extraction buffer (0.1% Igepal CA-630,10 
mM NaCl, 5 mM MgCl2, 0.1 mM PMSF, 10 mM Potassium phosphate buffer pH 7.4) and 
incubated on ice for 1 minute. Then, the cells were fixed by adding paraformaldehyde to a 
final concentration of 3% and incubating on ice for 1 hour. Fixed cells were washed once 
with 1×PBS and then stained with 20 μM Hoechst 33342 DNA dye for 10 minutes at 37°C 
in 1×PBS. DNA content and DNA-bound Clover-tagged Rb amounts were measured with a 
BD LSRII.UV flow cytometer.
Immunoblotting—Portions of harvested tumors were resuspended at 100 mg/mL in RIPA 
buffer supplemented with protease and phosphatase inhibitors. Next, we homogenized these 
tumor samples with pestles in tubes, and then sonicated the samples for 10 s at 50% 
amplitude on a Fisherbrand Model 120 Sonic Dismembrator. Cells cultured on dishes were 
collected by scraping in 1× PBS and lysed in RIPA buffer supplemented with protease and 
phosphatase inhibitors. Proteins from lysates were separated on a 10% SDS-PAGE gel and 
transferred to a nitrocellulose membrane using the iBlot 2 dry blotting system (Invitrogen 
IB21001).
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Membranes were incubated overnight at 4°C with the following antibodies: Phospho-Rb 
(Ser807/811) (D20B12) XP Rabbit mAb (Cell Signaling Technology #8516), Purified 
Mouse Anti-Human Retinoblastoma Protein Clone G3–245 (BD Biosciences 554136), 
Monoclonal ANTI-FLAG M2 antibody produced in mouse (Sigma-Aldrich F1804), E2F-1 
Antibody (Cell Signaling Technology #3742), and mouse monoclonal β-Actin Antibody 
N-21 (Santa Cruz Biotechnology sc-130656). The primary antibodies were detected using 
the fluorescently labeled secondary antibodies IRDye 680LT Goat anti-Mouse IgG (LI-COR 
926–68020) and IRDye 800CW Goat anti-Rabbit IgG (LI-COR 926–32211). Membranes 
were imaged on a LI-COR Odyssey CLx and analyzed with LI-COR ImageStudio software.
QUANTIFICATION AND STATISTICAL ANALYSIS
All values were expressed as means ± SEM except for tumor weight, which was expressed 
as medians and interquartile ranges. Statistical analyses were performed by Student’s t test 
(two-tailed) using GraphPad Prism 7. P values < 0.05 are considered statistically significant.
DATA AND SOFTWARE AVAILABILITY
Original images of autoradiographs and immunoblots are available at Mendeley Data under 
the following link: https://doi.org/10.17632/xy3xv64×2d.1.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Cyclin D, but not other cyclins, targets a C-terminal alphahelix docking motif 
on Rb
• Helix-based docking is shared by the p107 and p130 Rb-family members 
across metazoans
• Helix-based docking is a major driver of Rb phosphorylation and the G1/S 
transition
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Figure 1. Cyclin D-Cdk4,6 Complexes Target Rb for Phosphorylation by Docking a C-Terminal 
Helix
(A) Schematic of the cyclin-Cdk docking sites and the 14 accessible Cdk phosphorylation 
sites on Rb.
(B) Reported interactions and mutations of cyclin-Cdk docking sites on Rb.
(C) In vitro kinase assays using the denoted cyclin-Cdk complexes and histone H1 or 
variants of Rb. RbRxLmut lacks all C-terminal RxL sequences that dock cyclin hydrophobic 
patches. RbLxCxE cleft mut lacks the LxCxE docking cleft. RbΔC-term lacks the C-terminal 
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amino acids 893–928. The Coomassie-stained gels showing equal amounts of substrate used 
in each reaction are placed below each autoradiograph.
(D and E) Quantification of H1 kinase assays (D) and Rb kinase assays (E) using the 
denoted cyclin-Cdk complexes. Data are mean ± SEM; n = 2.
(F) The ratio of kinase activity of the denoted cyclin-Cdk complexes toward Rb and 
RbΔC-term. Data are mean ± SEM; n = 2.
(G) Helical wheel projection of the predicted Rb C-terminal helix. The black and gray 
arrows indicate the beginning and end of the helix, respectively. Circles represent 
hydrophilic residues, diamonds represent hydrophobic residues, triangles represent 
potentially negatively charged residues, and pentagons represent potentially positively 
charged residues. Colored amino acids correspond to alanine or proline substitutions in (H).
(H) In vitro kinase assays of Rb protein variants by cyclin D1-Cdk4. ΔCdk denotes Rb 
lacking the 14 Cdk phosphorylation sites. ΔHelix denotes Rb lacking the C-terminal helix 
amino acids 895–915. Helix mut. denotes an Rb variant where the predicted docking 
interface residues F897, L901, and R908 are substituted with alanines. Data are mean ± 
SEM; n = 2.
(I) Immunoblot analysis of a GST-pull-down binding assay. The GST-tagged Rb bait 
proteins were incubated with 3X FLAG-tagged cyclin D1 prey proteins. * Denotes a 
degradation product below full-length GST-Rb.
(J) Quantification cyclin D1-Cdk4 pulled down in (F). Data are mean ± SEM; n = 3.
(K and L) Quantification of in vitro kinase assays of the denoted Rb variant with (K) cyclin 
D1-Cdk4 or (L) cyclin E1-Cdk2. Data are mean ± SEM; n = 3.
(M) Comparison of the docking mechanisms recognized by cyclin D-Cdk4,6 and cyclin E-
Cdk2.
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Figure 2. The Rb C-Terminal Helix Is Sufficient to Recruit Cyclin D1-Cdk4,6 Complexes for 
Phosphorylation
(A) Schematic of the engineered GST-Cdk phosphorylation site fusion protein containing a 
GST tag and the Rb amino acids 775–787 containing a single Cdk site fused to either no 
docking site, the Rb C-terminal helix docking site (+Helix), the Rb C-terminal helix docking 
site with the three interface residues substituted with alanines (+Helix mut.), or the Rb C-
terminal helix docking site in reverse (+Helix rev.).
(B and C) In vitro kinase assays of the indicated engineered GST-Cdk phosphorylation site 
fusion protein by (B) cyclin D1-Cdk6 or(C) cyclin E1-Cdk2. Data are mean ± SEM; n = 3.
(D and E) Schematic of docking interaction between cyclin D-Cdk4,6 complexes and (D) 
the engineered GST-Cdk phosphorylation site fused to the Rb C-terminal helix docking site 
in comparison to (E) mutant versions of the engineered GST-Cdk phosphorylation site 
fusion protein.
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Figure 3. D-Type Cyclins Recognize the Rb C-Terminal Helix
(A) In vitro kinase assays with all six cyclin D-Cdk4,6 complexes and the denoted Rb 
variants. The Coomassie-stained gels showing equal amounts of substrate used in each 
reaction are placed below each autoradiograph. Fold changes ± SEM of wild type to Helix 
mutant phosphorylation are: 30 ±10for cyclin D1-Cdk4; 19 ± 3 for cyclin D2-Cdk4; 90 ± 20 
for cyclin D3-Cdk4; 17 ± 6 for cyclin D1-Cdk6; 19 ± 8 for cyclin D2-Cdk6; 30 ± 20 for 
cyclin D3-Cdk6. Representative experiments shown (out of two independent experiments).
(B) In vitro kinase assays of the denoted Rb variant with cyclin D1-Cdk6 or cyclin 
D1HP mut.-Cdk6. The Coomassie-stained gels showing equal amounts of substrate used in 
each reaction are placed below each autoradiograph. Representative experiments shown (out 
of two independent experiments).
(C) In vitro kinase assays using the denoted cyclin D1-Cdk6 complexes with GST-Rb775–
787(S780)+Helix docking or GST-Rb775–787(S780)+RxL docking. Cyclin D1HPmut.- 
denotes mutation of the hydrophobic patch on cyclin D1. Cyclin D1LxCxE mut denotes 
mutation of the LxCxE motif on cyclin D1. The Coomassie-stained gels showing equal 
amounts of substrate used in each reaction are placed below each autoradiograph. 
Representative experiments shown (out of three independent experiments).
(D and E) Quantification of the phosphorylation of the engineered GST-Cdk 
phosphorylation site fusion protein containing helixdocking from Rb (+Helix) or RxL 
docking from Cdc6 (+RxL) by wild type cyclin D1-Cdk6 versus (D) cyclin D1HP mut -Cdk6 
or (E) cyclin D1LxCxE mut -Cdk6. Data are mean ± SEM; n = 3.
(F) In vitro kinase assays with cyclin D1 fused to Cdk2. GST-Rb775–787(S780) without 
docking or GST-Rb775–787(S780)+Helix docking were used as substrates. The Coomassie-
stained gel showing equal amounts of substrate used in each reaction is placed below the 
autoradiograph. Representative experiments shown (out of two independent experiments).
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(G) Schematic of the docking interactions between cyclin D1, D2, and D3 complexes and 
their substrates. Cyclins D1–D3 are capable of recognizing substrate proteins through helix-
based docking, independent of the Cdk present in the complex.
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Figure 4. A C-Terminal Docking Helix Is Present in the Metazoan Rb Protein Family
(A–D) Helical wheel projection of the predicted C-terminal helix for human (A) p107 and 
(C) p130, and in vitro kinase assays of human (B) p107 and (D) p130 variants by cyclin D1-
Cdk4. DC-term denotes truncating p107 after amino acid position 1014 and p130 after 
amino acid position 1122. Helix mut. denotes alanine substitution of the predicted docking 
interface residues indicated in blue and green in (A) and (C). Data are mean ± SEM; n = 2.
(E) C-terminal helix sequence motif generated using 682 sequences of metazoan Rb family 
members. In the logo, blue denotes hydrophilic residues, green denotes neutral amino acids, 
and black denotes hydrophobic amino acids. Below the logo, C-terminal helix residues for 
Rb, p107, and p130 are aligned. The C-terminal helix residues that were tested for 
importance to cyclin D-docking are colored according to Figure 1G and (A) and (C).
(F) A C-terminal Rb helix was not found outside metazoan proteome sequences.
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Figure 5. The Cyclin D-Cdk4,6-Rb Interaction Promotes the G1/S Transition, Rb Dissociation 
from Chromatin, and E2F1 Activation
(A) Map of PiggyBac integration constructs containing doxycycline-inducible human RB1 
gene fused to fluorescent Clover and 3X FLAG affinity tag sequences.
(B) Composite phase contrast and Clover fluorescence images showing expression of 
Clover-3X FLAG-Rb in HMECs with and without 500 ng/mL doxycycline.
(C-E) Cell-cycle analysis by EdU incorporation and DAPI staining (data are mean ± SEM; n 
= 2) (C), cell size in G1 (representative experiments shown, out of three independent 
experiments) (D), and amount of chromatin-bound Rb in G1 (representative experiments 
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shown, out of three independent experiments) (E) in HMECs expressing Clover-3FLAG 
alone (empty), wild type Rb, or the indicated mutant Rb following a 48-h induction with 
doxycycline (500 ng/mL). RbLxCxE cleft mut. lacks the LxCxE docking cleft. RbHellx mut. 
denotes an Rb variant where the predicted docking interface residues F897, L901, and R908 
are substituted with alanines. RbLxCxE cleft+Helix mut. contains both indicated mutations. 
RbΔCdk lacks the 14 Cdk phosphorylation sites. Listed in the upper right of each histogram 
are median FSC for (D) and Clover-3FLAG-Rb for (E).
(F) Schematic of Rb phosphorylation time course experiment. T98G cells were arrested by 
serum starvation (−FBS), Rb was induced (+dox), and samples were collected at 0, 4, 8, 12, 
and 24 h after release (+10% FBS, +dox).
(G) Immunoblot analysis of lysates from Rb phosphorylation time course described in (F) 
with the denoted antibodies. Representative experiments shown (out of three independent 
experiments).
(H and I) Quantification of (H) phospho-Rb(807/811)over total Clover-3FLAG-Rband (I) 
E2F1 from Rb phosphorylation time course in (G). Data are mean ± SEM; n = 3.
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Figure 6. Disruption of the Cyclin D-Cdk4,6-Rb Interaction Slows Tumor Growth
(A) Schematic of mouse experiment. PiggyBac integration constructs containing 
doxycycline-inducible mouse Rb1 fused to fluorescent Clover and 3FLAG affinity tag 
sequences were transfected into Kras+/G12D; Trp53−/− mouse pancreatic ductal 
adenocarcinoma cells (CKP-2167). Approximately 1 million CKP-2167 cells expressing 
variants of doxycycline-inducible mouse Rb were allografted by subcutaneous implantation. 
After 5 days of engraftment and growth, mice were given water supplemented with 
doxycycline (2 mg/mL) for 2 weeks.
(B) Fold change in tumor volume compared to day 0 were calculated from caliper 
measurements. Data are mean ± SEM. A table of p values for all fold-change comparisons 
can be found in Figure S7B. n = 12 for empty, RbWT, RbHelix mut., and RbΔCdk.
(C) Median tumor weight and interquartile ranges 15 days after doxycycline induction of 
either empty vector, wild type Rb, or RbHelix mut. n.s., *p > 0.05, **p ≤ 0.05, and ***p ≤ 
0.001. n = 4 for empty, n = 10 for RbWT, and n = 10 for RbHelix mut.
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Figure 7. Cyclin D-Cdk4,6 Inactivates Rb through Multiple, Specific Docking Interactions to 
Drive Cell-Cycle Progression
(A) Schematic of the multiple docking interactions between cyclin D and Rb. The LxCxE 
cleft in the Rb pocket interacts with an LxCxE motif at the N terminus of cyclin D. The RxL 
motifs on the C terminus of Rb interact with the hydrophobic patch (HP) of cyclin D. The C-
terminal helix of Rb interacts with an unknown part of cyclin D. Together, these interactions 
contribute to how the Cdk4 and Cdk6 active sites target the 14 accessible Cdk sites on Rb.
(B) A model for the major functions of cyclin D-Cdk4,6 complexes. Cyclin D-Cdk4,6 
docks, phosphorylates, and inactivates Rb to promote S Phase. Cyclin D-Cdk4,6 also 
promotes cell proliferation and survival through phosphorylation of other substrate proteins.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Phospho-Rb (Ser807/811) (D20B12) XP Rabbit mAb Cell Signaling Technology Cat#8516; RRID: AB_11178658
Purified Mouse Anti-Human Retinoblastoma Protein Clone 
G3–245
BD Biosciences Cat#554136; RRID: AB_395259
Monoclonal ANTI-FLAG M2 antibody produced in mouse Sigma-Aldrich Cat#F1804; RRID: AB_262044
E2F-1 Antibody Cell Signaling Technology Cat#3742; RRID: AB_2096936
Mouse monoclonal β-Actin Antibody N-21 Santa Cruz Biotechnology Cat#sc-130656; RRID: AB_2223228
IRDye 680LT Goat anti-Mouse IgG LI-COR Cat#926–68020; RRID: AB_10706161
IRDye 800CW Goat anti-Rabbit IgG LI-COR Cat#926–32211; RRID: AB_621843
ANTI-FLAG M2 affinity agarose beads Sigma-Aldrich Cat#A2220; RRID: AB_10063035
Bacterial and Virus Strains
E. coli BL21 Agilent Cat#230245
E. coli DH5α Agilent Cat#200231
Chemicals, Peptides, and Recombinant Proteins
Palbociclib Santa Cruz Biotechnology Cat#sc-478943
FuGene HD reagent Promega Cat#E2311
Zeocin Selection Reagent GIBCO Cat#R25001
Doxycycline, Hyclate, CAS 24390–14-5, Calbiochem Cat#324385–1GM
Matrigel Basement Membrane Matrix Corning Cat#356237
L-Glutathione reduced Sigma-Aldrich Cat#G4251
Glutathione-Agarose Sigma-Aldrich Cat#G4510
3X FLAG peptide Sigma-Aldrich Cat#F4799
[γ−32P] ATP PerkinElmer Cat# BLU502Z250UC
HistoneH1 protein EMD Millipore Cat#14–155
DAPI (4’,6-Diamidino-2-Phenylindole, Dilactate) Invitrogen Cat#D3571; RRID: AB_2307445
Hoechst 33342, Trihydrochloride, Trihydrate Invitrogen Cat#H1399
Critical Commercial Assays
Click-iT Plus EdU Alexa Fluor 594 Flow Cytometry Assay 
Kit
Invitrogen Cat#C10646
Deposited Data
Raw data and images Mendeley Data https://doi.org/10.17632/xy3xv64x2d.1
Experimental Models: Cell Lines
Human: HMEC-hTERT1 Dr. S. Elledge Sack et al., 2018
Human: T98G Dr. C. Shwarz Schwarz et al., 2018
Human: U-2 OS A.C. Chaikovsky N/A (unpublished)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Human: U-2 OS RB1−/− A.C. Chaikovsky N/A (unpublished)
Mouse: CKP-2167 Dr. P. K. Mazur Mazur et al., 2015
Experimental Models: Organisms/Strains
Mouse: NSG The Jackson Laboratory via Dr. M. 
Winslow
Cat#005557; RRID: IMSR_JAX:
005557
Budding yeast: yBT000 W303 MATa bar1::HISG cdc28:: 
cdc28-as1 sic1Δ::URA3
Dr. M. Kõivomägi Kõivomägi et al., 2011
Budding yeast: yBT004 W303 MATa bar1::HISG cdc28:: 
cdc28-as1 sic1Δ::URA3 LexA-ER-haB112::HIS3
Dr. M. Kõivomägi Kõivomägi et al., 2011
Recombinant DNA
Tet-On 3G Inducible Expression System (pCMV-Tet3G 
Regulator Plasmid & pTRE3G Response Plasmid)
Clontech Laboratories via Dr. A. 
Shariati
Cat#631168
pGEX-4T-1 GE Healthcare Cat#28–9545-49
PBSKHRbc Dr. R. Weinberg via Addgene Cat#1761; RRID: Addgene_1761
pCMV HA hRb delta CDK Dr. S. Dowdy via Addgene Cat#58906; RRID: Addgene_58906
See Table S3 for all plasmids generated for this study N/A N/A
Other
MEGM Mammary Epithelial Cell Growth Medium Lonza Cat#CC-3150
DMEM With 4.5g/L Glucose, Sodium Pyruvate; Without L-
Glutamine, Phenol Red
Corning Cat#17205CV
Fetal Bovine Serum, qualified, heat inactivated, USDA- 
approved regions
GIBCO Cat#10438026
Penicillin Streptomycin 100X Solution HyClone Cat#SV30010
L-Glutamine, 200mM Solution HyClone Cat#SH30034.02
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